Inhibition of the RNA translation factor, eIF4E, as a novel treatment strategy in Ewing Sarcoma

Inhibition of the RNA translation factor, eIF4E, as a novel treatment strategy in Ewing Sarcoma

Julia Travagline 12/14/25 Julia Travagline 12/14/25

Inhibition of the RNA translation factor, eIF4E, as a novel treatment strategy in Ewing Sarcoma

Inhibition of the RNA translation factor, eIF4E, as a novel treatment strategy in Ewing Sarcoma

Dr. John Prensner, M.D., Ph.D. – The Regents of the University of Michigan, Ann Arbor, MI

Tumor-specific PROTAC development as a new therapeutic approach for osteosarcoma

Julia Travagline 12/14/25 Julia Travagline 12/14/25

Tumor-specific PROTAC development as a new therapeutic approach for osteosarcoma

Tumor-specific PROTAC development as a new therapeutic approach for osteosarcoma

Dr. Gunda Georg, Ph.D. – Regents of the University of Minnesota - Twin Cities, Minneapolis, MN

Julia Travagline 12/14/25 Julia Travagline 12/14/25

Dissecting Ewing Sarcoma On-Chip for Better Therapeutics

Dissecting Ewing Sarcoma On-Chip for Better Therapeutics

Dr. Yuan Gao, Ph.D. – Case Western Reserve University - School of Medicine, Cleveland, OH

Julia Travagline 12/8/21 Julia Travagline 12/8/21

First-in-class oral inhibitor of TGF-beta receptor in humanized mouse model of advanced osteosarcoma

First-in-class oral inhibitor of TGF-beta receptor in humanized mouse model of advanced osteosarcoma

Case Western Reserve University School of Medicine, Cleveland, OH

Julia Travagline 8/9/21 Julia Travagline 8/9/21

Targeting Beta-Catenin Mediated Activity in Metastatic Osteosarcoma

Targeting Beta-Catenin Mediated Activity in Metastatic Osteosarcoma

Baylor College of Medicine, Houston, TX